Skip to main content
Erschienen in: Osteoporosis International 6/2011

01.06.2011 | Original Article

Plasma osteoprotegerin, arterial stiffness, and mortality in normoalbuminemic Japanese hemodialysis patients

verfasst von: A. Nakashima, J. J. Carrero, A. R. Qureshi, T. Hirai, N. Takasugi, T. Ueno, Y. Taniguchi, B. Lindholm, N. Yorioka

Erschienen in: Osteoporosis International | Ausgabe 6/2011

Einloggen, um Zugang zu erhalten

Abstract

Summary

A high circulating osteoprotegerin (OPG) level may be a risk factor for vascular calcification and mortality in hemodialysis patients. OPG and pulse wave velocity (PWV) were measured at baseline in 151 normoalbuminemic, long-term (>3 years) Japanese hemodialysis patients who were prospectively followed for 6 years. In long-term normoalbuminemic Japanese hemodialysis patients, OPG levels were strongly linked with both arterial stiffness and worse outcome.

Introduction

A high circulating OPG level is reported to be a risk factor for vascular calcification and mortality in Western chronic kidney disease (CKD) patients but it is not known if this is true for Japanese CKD patients, where a different risk profile may operate.

Methods

OPG and PWV were measured at baseline in 151 normoalbuminemic, long-term (>3 years) Japanese hemodialysis patients (median age 62 years) who were prospectively followed for 6 years.

Results

OPG levels were associated in multivariate analysis with age, dialysis vintage, history of cardiovascular disease (CVD) and parathyroid hormone levels. C-reactive protein levels did not correlate with OPG. Patients with clinical history of CVD had significantly higher OPG levels and OPG levels were positively correlated to PWV, an index of arterial stiffness. These associations were independent of age, sex, dialysis vintage, and diabetes. During the follow-up period, 40 deaths, including 25 cardiovascular deaths, were recorded. In crude analysis, each unit of increase in OPG was associated with increased all-cause (hazard ratios 1.14, 95% confidence interval 1.08–1.20) and CVD mortality (1.14 [1.07–1.21]), which persisted after adjustment for age, sex, dialysis vintage, diabetes, and baseline CVD (1.12 [1.05–1.19] and 1.11 [1.02–1.19], all-cause and CVD mortality, respectively).

Conclusions

In long-term normoalbuminemic Japanese hemodialysis patients, with low prevalence of inflammation, OPG levels were strongly linked with both arterial stiffness and worse outcome.
Literatur
1.
Zurück zum Zitat Cannata-Andía JB, Rodríguez-García M, Carrillo-López N, Naves-Díaz M, Díaz-López B (2006) Vascular calcifications: pathogenesis, management, and impact on clinical outcomes. J Am Soc Nephrol 17:S267–S273PubMedCrossRef Cannata-Andía JB, Rodríguez-García M, Carrillo-López N, Naves-Díaz M, Díaz-López B (2006) Vascular calcifications: pathogenesis, management, and impact on clinical outcomes. J Am Soc Nephrol 17:S267–S273PubMedCrossRef
2.
Zurück zum Zitat Blacher J, Demuth K, Guerin AP, Safar ME, Moatti N, London GM (1998) Influence of biochemical alterations on arterial stiffness in patients with end-stage renal disease. Arterioscler Thromb Vasc Biol 18:535–541PubMed Blacher J, Demuth K, Guerin AP, Safar ME, Moatti N, London GM (1998) Influence of biochemical alterations on arterial stiffness in patients with end-stage renal disease. Arterioscler Thromb Vasc Biol 18:535–541PubMed
3.
Zurück zum Zitat London GM, Marchais SJ, Guerin AP, Pannier B (2004) Arterial stiffness: pathophysiology and clinical impact. Clin Exp Hypertens 26:689–699PubMedCrossRef London GM, Marchais SJ, Guerin AP, Pannier B (2004) Arterial stiffness: pathophysiology and clinical impact. Clin Exp Hypertens 26:689–699PubMedCrossRef
4.
Zurück zum Zitat Simonet WS, Lacey DL, Dunstan CR et al (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309–319PubMedCrossRef Simonet WS, Lacey DL, Dunstan CR et al (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309–319PubMedCrossRef
5.
Zurück zum Zitat Lacey DL, Timms E, Tan HL et al (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165–176PubMedCrossRef Lacey DL, Timms E, Tan HL et al (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165–176PubMedCrossRef
6.
Zurück zum Zitat Bucay N, Sarosi I, Dunstan CR et al (1998) Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12:1260–1268PubMedCrossRef Bucay N, Sarosi I, Dunstan CR et al (1998) Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12:1260–1268PubMedCrossRef
7.
Zurück zum Zitat Min H, Morony S, Sarosi I et al (2000) Osteoprotegerin reverses osteoporosis by inhibiting endosteasl osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 192:463–474PubMedCrossRef Min H, Morony S, Sarosi I et al (2000) Osteoprotegerin reverses osteoporosis by inhibiting endosteasl osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 192:463–474PubMedCrossRef
8.
Zurück zum Zitat Kazama JJ, Shigematsu T, Yano K et al (2002) Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis 39:525–532PubMedCrossRef Kazama JJ, Shigematsu T, Yano K et al (2002) Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis 39:525–532PubMedCrossRef
9.
Zurück zum Zitat Nitta K, Akiba T, Uchida K et al (2003) The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. Am J Kidney Dis 42:303–309PubMedCrossRef Nitta K, Akiba T, Uchida K et al (2003) The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. Am J Kidney Dis 42:303–309PubMedCrossRef
10.
Zurück zum Zitat Barreto DV, Barreto FC, Carvalho AB et al (2005) Coronary calcification in hemodialysis patients: the contribution of traditional and uremia-related risk factors. Kidney Int 67:1576–1582PubMedCrossRef Barreto DV, Barreto FC, Carvalho AB et al (2005) Coronary calcification in hemodialysis patients: the contribution of traditional and uremia-related risk factors. Kidney Int 67:1576–1582PubMedCrossRef
11.
Zurück zum Zitat Morena M, Terrier N, Jaussent I et al (2006) Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol 17:262–270PubMedCrossRef Morena M, Terrier N, Jaussent I et al (2006) Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol 17:262–270PubMedCrossRef
12.
Zurück zum Zitat Speer G, Fekete BC, El Hadj Othmane T et al (2008) Serum osteoprotegerin level, carotid-femoral pulse wave velocity and cardiovascular survival in haemodialysis patients. Nephrol Dial Transplant 23:3256–3262PubMedCrossRef Speer G, Fekete BC, El Hadj Othmane T et al (2008) Serum osteoprotegerin level, carotid-femoral pulse wave velocity and cardiovascular survival in haemodialysis patients. Nephrol Dial Transplant 23:3256–3262PubMedCrossRef
13.
Zurück zum Zitat Nakamura S, Ishibashi-Ueda H, Niizuma S, Yoshihara F, Horio T, Kawano Y (2009) Coronary calcification in patients with chronic kidney disease and coronary artery disease. Clin J Am Soc Nephrol 4:1892–1900PubMedCrossRef Nakamura S, Ishibashi-Ueda H, Niizuma S, Yoshihara F, Horio T, Kawano Y (2009) Coronary calcification in patients with chronic kidney disease and coronary artery disease. Clin J Am Soc Nephrol 4:1892–1900PubMedCrossRef
14.
Zurück zum Zitat Coodkin DA, Bragg-Gresham JL, Koenig KG et al (2003) Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: The dialysis outcomes and practice patterns study (DOPPS). J Am Soc Nephrol 14:3270–3277CrossRef Coodkin DA, Bragg-Gresham JL, Koenig KG et al (2003) Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: The dialysis outcomes and practice patterns study (DOPPS). J Am Soc Nephrol 14:3270–3277CrossRef
15.
Zurück zum Zitat Matsubara K, Stenvinkel P, Qureshi AR et al (2009) Inflammation modifies the association of osteoprotegerin with mortality in chronic kidney disease. J Nephrol 22:774–782PubMed Matsubara K, Stenvinkel P, Qureshi AR et al (2009) Inflammation modifies the association of osteoprotegerin with mortality in chronic kidney disease. J Nephrol 22:774–782PubMed
16.
Zurück zum Zitat Honda H, Ueda M, Kojima S et al (2009) Assessment of myeloperoxidase and oxidative alpha1-antitrypsin in patients on hemodialysis. Clin J Am Soc Nephrol 4:142–151PubMedCrossRef Honda H, Ueda M, Kojima S et al (2009) Assessment of myeloperoxidase and oxidative alpha1-antitrypsin in patients on hemodialysis. Clin J Am Soc Nephrol 4:142–151PubMedCrossRef
17.
Zurück zum Zitat Misra M, Soyka LA, Miller KK et al (2003) Serum osteoprotegerin in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab 88:3816–3832PubMedCrossRef Misra M, Soyka LA, Miller KK et al (2003) Serum osteoprotegerin in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab 88:3816–3832PubMedCrossRef
18.
Zurück zum Zitat Kazama JJ, Omori K, Takahashi N et al (2005) Maxacalcitol therapy decreases circulating osteoprotegerin levels in dialysis patients with secondary hyperparathyroidism. Clin Nephrol 64:64–68PubMed Kazama JJ, Omori K, Takahashi N et al (2005) Maxacalcitol therapy decreases circulating osteoprotegerin levels in dialysis patients with secondary hyperparathyroidism. Clin Nephrol 64:64–68PubMed
19.
Zurück zum Zitat Payne RB, Little AJ, Williams RB, Milner JR (1973) Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J 4:643–646PubMedCrossRef Payne RB, Little AJ, Williams RB, Milner JR (1973) Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J 4:643–646PubMedCrossRef
20.
Zurück zum Zitat Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502PubMed Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502PubMed
21.
Zurück zum Zitat Yamashina A, Tomiyama H, Takeda K et al (2002) Validity, reproducibility, and clinical significance of noninvasive brachial–ankle pulse wave velocity measurement. Hypertens Res 25:359–364PubMedCrossRef Yamashina A, Tomiyama H, Takeda K et al (2002) Validity, reproducibility, and clinical significance of noninvasive brachial–ankle pulse wave velocity measurement. Hypertens Res 25:359–364PubMedCrossRef
22.
Zurück zum Zitat Suzuki E, Kashiwagi A, Nishio Y et al (2001) Increased arterial wall stiffness limits flow volume in the lower extremities in type 2 diabetic patients. Diab Care 24:2107–2114CrossRef Suzuki E, Kashiwagi A, Nishio Y et al (2001) Increased arterial wall stiffness limits flow volume in the lower extremities in type 2 diabetic patients. Diab Care 24:2107–2114CrossRef
23.
Zurück zum Zitat Heinzl H, Kaider A (1997) Gaining more flexibility in Cox proportional hazards regression models with cubic spline functions. Comput Methods Programs Biomed 54:201–208PubMedCrossRef Heinzl H, Kaider A (1997) Gaining more flexibility in Cox proportional hazards regression models with cubic spline functions. Comput Methods Programs Biomed 54:201–208PubMedCrossRef
24.
Zurück zum Zitat Sigrist MK, Levin A, Er L, McIntyre CW (2009) Plasma osteoprotegerin is an independent risk factor for mortality and an early biomarker of coronary vascular calcification in chronic kidney disease. Nephrol Dial Transplant 24:3157–3162PubMedCrossRef Sigrist MK, Levin A, Er L, McIntyre CW (2009) Plasma osteoprotegerin is an independent risk factor for mortality and an early biomarker of coronary vascular calcification in chronic kidney disease. Nephrol Dial Transplant 24:3157–3162PubMedCrossRef
25.
Zurück zum Zitat Mesquita M, Demulder A, Damry N et al (2009) Plasma osteoprotegerin is an independent risk factor for mortality and an early biomarker of coronary vascular calcification in chronic kidney disease. Clin Chem Lab Med 47:339–346PubMedCrossRef Mesquita M, Demulder A, Damry N et al (2009) Plasma osteoprotegerin is an independent risk factor for mortality and an early biomarker of coronary vascular calcification in chronic kidney disease. Clin Chem Lab Med 47:339–346PubMedCrossRef
26.
Zurück zum Zitat Carrero JJ, Stenvinkel P (2009) Persistent inflammation as a catalyst for other risk factors in chronic kidney disease: a hypothesis proposal. Clin J Am Soc Nephrol 4:S49–S55PubMedCrossRef Carrero JJ, Stenvinkel P (2009) Persistent inflammation as a catalyst for other risk factors in chronic kidney disease: a hypothesis proposal. Clin J Am Soc Nephrol 4:S49–S55PubMedCrossRef
27.
Zurück zum Zitat Nishiura R, Fujimoto S, Sato Y et al (2009) Elevated osteoprotegerin levels predict cardiovascular events in new hemodialysis patients. Am J Nephrol 29:257–263PubMedCrossRef Nishiura R, Fujimoto S, Sato Y et al (2009) Elevated osteoprotegerin levels predict cardiovascular events in new hemodialysis patients. Am J Nephrol 29:257–263PubMedCrossRef
28.
Zurück zum Zitat Price PA, June HH, Buckley JR, Williamson MK (2001) Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol 21:1610–1616PubMedCrossRef Price PA, June HH, Buckley JR, Williamson MK (2001) Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol 21:1610–1616PubMedCrossRef
Metadaten
Titel
Plasma osteoprotegerin, arterial stiffness, and mortality in normoalbuminemic Japanese hemodialysis patients
verfasst von
A. Nakashima
J. J. Carrero
A. R. Qureshi
T. Hirai
N. Takasugi
T. Ueno
Y. Taniguchi
B. Lindholm
N. Yorioka
Publikationsdatum
01.06.2011
Verlag
Springer-Verlag
Erschienen in
Osteoporosis International / Ausgabe 6/2011
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-010-1377-0

Weitere Artikel der Ausgabe 6/2011

Osteoporosis International 6/2011 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Arthroskopie kann Knieprothese nicht hinauszögern

25.04.2024 Gonarthrose Nachrichten

Ein arthroskopischer Eingriff bei Kniearthrose macht im Hinblick darauf, ob und wann ein Gelenkersatz fällig wird, offenbar keinen Unterschied.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 Leitsymptom Rückenschmerzen Nachrichten

Personen mit chronischen Rückenschmerzen, die von einfühlsamen Ärzten und Ärztinnen betreut werden, berichten über weniger Beschwerden und eine bessere Lebensqualität.

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.